Rayence said Wednesday that it has signed a joint research agreement with Yonsei University's Office of Research Affairs/University Industry Foundation to develop a next-generation sensor technology.
|Rayence CEO Kim Tae-woo (left) and Yonsei University’s College of Engineering Dean Hong Dae-sik shake hands after signing the cooperation agreement at Yonsei University in Sinchon, Seoul, on Wednesday.|
Under the accord, the two institutions will jointly operate Rayence’s Center of Advanced sensor Research & Innovation (CARI).
The company plans to collaborate with various research teams from the university, including those led by Professors Chae Young-cheol and Ahn Jong-hyun of the Department of Electronics and Professor Kim Jin-Sung of the Department of Radiation Oncology.
With the establishment of the research center, the company will be able to analyze and forecast technological trends with Yonsei University through joint R&D, ranging from the design of detectors to clinical applications.
Researchers will conduct fusion research such as enabling the application of developed detector technology in the actual hospital environment, and material development for X-ray imaging system technology.
Based on such fusion researches, the company plans to find out the functions that will become a differentiating advantage in the field of industrial X-ray and radiotherapy, it said.
Rayence will also continue to develop image-assisted detectors for radiation cancer therapy as well as original technologies that are well-known in the medical/industrial inspection market, such as high-resolution and high-speed x-ray detector designed for in-line inspection systems.
“Through CARI, we plan to develop a next-generation high-performance detector technology that can be practically applied to the market,” said Professor Chae, who is also CARI’s first director. “To do so, we need close cooperation between Yonsei University and Rayence.”
Rayence also showed high expectations for the newly signed agreement.
“With the cooperation from Yonsei University, the company expects to gain a competitive edge in the detection market by applying cutting-edge technologies,” Rayence CEO Kim Tae-woo said. “Also, the agreement has great significance since it conducts fusion research with world-class experts from detector development to clinical evaluation.
<© Korea Biomedical Review, All rights reserved.>